If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
& it almost always tanks automatically?
Open a short in the UK and the company collapses.
FCA WTF?
Promising Q3 results today. Plenty of room for SP to re-rate upwards.
https://www.lse.co.uk/news/SN./smith-nephew-expects-strong-full-year-results-after-solid-q3-b4xsiqom9lrn9wg.html
Well Jason, perhaps you would now care to explain exactly what the "bent Institutional Investors" knew that wasn't in the half year forecast?
HSBC raises Smith & Nephew to 'buy' - price target 1,220 pence
On August 4th I posted these shares had lost 15% in a month - as of today they’ve lost a further 12%. This should be an embarrassment for the senior team. Incompetent is probably too kind a word.
Great products, great reputation, great markets to be operating in …… what’s so difficult here??
The bent institutional investors obviously already know what the. trading results will be like next week.
£1.00 at this rate, bloody ridiculous outfit!
Apologies for all the typos in my last, but it is early sunday morning :o)
Hopefuly they will continue to reduce this week prior to results the follwoing week. If results are good then hopefully we will get a bit of movement back up again.
I appreciate the comments about the company not doing so good, but profit is profit and if you can continue to increase profit, even if on a higher runover with less margin, then in my eyes that is a good thing. Sa here rubbing my wounds this mornign but wont sell as still convinced this will come good, even if we ahve to wait for the Board to appoint a new CEO.
Plymouth Mike you forgot to mention Citadel the short selling hedgies manipulating the SP here to their benefit.
How about they are not doing as well as they were a few years ago/ before Covid.
I am surprised at the poor sp here tbh.
Cheap as chips - tuck away
I'd rule out your last bullet point and expect a similar recovery to Ypugov which followed a similar downward trajectory until they published their results (i.e. what the IIs knew nothing in advance).
Motley Fool's timely thoughts
https://www.fool.co.uk/2023/10/16/are-smith-nephew-shares-about-to-explode/
Well unfortuantely the price has continiued to fall since my last post as predicted so Ive only got myslef to blame for hanging onto these shares as a long term investor.
Unless someone can show me some negative news which has been formally posted and Ive missed, then in my opionion one of the following must be happening:
The City is showing its total disregard for the Board members and their support of the CEO
The price is being driven down by big investors / hedge funds to encourage a Take over
The big institutional investors have been made aware of news which is not yet out in public pending the latest Company update
Anyone care to add their views?
Weak leadership imho. Just dreadful.
Thinking of exiting my position at a loss and recouping elsewhere (CPI).
GLA DYOR
Fully agree Mulder, weight loss drugs a total irrelevance.
On a separate note, you might want to make your severely obese patients aware of a clinical approved oral alternative to the injections called Slimbiome Medical
https://optibiotix.com/product/slimbiome-medical/
If anyone is shorting this on the back of the hype and hysteria of weight loss drugs in the US then you have made a gross miscalculation. In the UK I can tell you less than 1% of my patients are on these drugs. They are incredibly expensive and in very short supply meaning they are often out of stock. No oral version. Injection only. Side effects are numerous and troublesome. Even in the US only the rich/celebs are using them to now.
Finally osteoarthritis is seen in all body types not just the obese. I have seen terrible OA in thin individuals. TKR and THR numbers will not be going down any time soon. If anything they will surge given the growing population and people are living longer.
Sports division with the right CEO should be booming.
China back fully open also.
So this hysteria is all crap. Any excuse to short...
Investorrelations.global@smith-nephew.com
Sadly with this back at 2014 levels it is yet another FTSE stock that has gone nowhere, IMO it's share price illegally suppressed by hedge funds who hammer UK listed stocks without always any good justifiable reason and then lo and behold an overseas predator, usually American, comes and picks them up on the cheap. Aviva today. Happens again and again. Stryker is in the same sector over in the States - it has seen its stock rise 65% in just 5 years.
I haven't contacted Investor relations again at this point but my pen is poised.
There is something defiantly not right at the top and looking at Director Holdings I am sure many of them will be watching the reduction in their assets very closely and wondering where this is headed, as will many big shareholders. Of course, there is also always the consideration that the Market knows something else and the share price is being manipulated in readiness for that, but I don't think that ever happens and that's probably just a figment of my imagination :o)
I don't see why the shares should fall 'significantly further'? Yes it is a weak market but we are entering a seasonally strong period. Rates have peaked and will be cut fairly soon. This was up around £19 pre Covid. Any takeover offer would have to be in that ball park. I see Soames appointment as a positive. The board shake up shows Deepak is under huge pressure. Have you contacted Investor Relations again recently?I don't care what his reasons were for the share sale shortly after appointment but it stunk and went down very badly with stakeholders. He seems out of his depth.
Let's wait and see Plymouth. At the Half Year we were told "Strong H1 growth with FY revenue guidance raised, 12-Point Plan on track" and "2023 Full Year Outlook1,2
· Increased full year underlying revenue growth guidance of 6.0% to 7.0% (previously 5.0% to 6.0%)"
· Unchanged trading profit margin guidance, expected to be at least 17.5%" . So if things were materially different the market would have to be told
Whilst I agree that time needs to be given for a new plan to work, we are now over half way through the proposed programme and the price continues to fall. There will be City analysts who have for more insight into what is going on behind the scenes and I think the large sell off at the end of last month signifies further downward pressure on this share under the current leadership. I am a long term share holder and expressed my concerns to the Board very shortly after the appointment of the CEO. Lets see what happens, but I'm now expecting the price to fall significantly further. If a take over is on the horizon, then any uplift in the share price for an offer is not going to help as an offer of 30% over the current share price would only be circa £12.50/share. Would be interested to hear what other peoples views are on this matter and what they think a reasonable offer price for the share would be if there was a takeover bid.
Mulder, he was only appointed effectively from 2022 and after a few months came up with a 2 year 12 point plan lasting two years from July 2022 to improve the Business. As I said, let's see how things are progressing against that turnaround plan before passing judgement
"In July 2022 we announced a comprehensive 12-point plan to drive better execution at pace, in order to take the business forward and deliver on our Strategy for Growth pillars to Strengthen and Accelerate. This plan is focused on:
· Fixing Orthopaedics
· Improving productivity
· Accelerating growth in Advanced Wound Management and Sports Medicine & ENT
During the quarter we embedded the teams and structures to drive this work and established the internal KPIs to monitor progress and drive accountability.
While we expect the work to deliver the full plan to take two years, we are making meaningful early progress, including:
· Improving logistics and updating our demand and supply planning process to bring a deeper level of specificity and collaboration between our operations and commercial teams;
· Reducing the value of overdue orders in US Orthopaedics by more than 15% since the peak in the first half of the year; and
· Moving Orthopaedics instrument sets to more active customer accounts, with 80% of the first phase completed in the US by quarter end.
Further work is proceeding across the 12-point plan, and we will continue to update on progress in future trading updates."
More management churn
https://neuronewsinternational.com/medtronic-names-paolo-di-vincenzo-president-of-its-neuromodulation-business/
Nope, he has had a year. We want him out. His director dealings have not helped.